

Special Issue

Vascular Pathologies in the Omics Era

Message from the Guest Editor

Vascular pathology encompasses a spectrum of conditions impacting blood vessels and represents a pivotal area of inquiry within the burgeoning discipline of omics. This field involves a comprehensive analysis of diverse biomolecules on a large scale. In this omics era, researchers harness advanced technologies, including genomics, transcriptomics, proteomics, and metabolomics, in order to gain deeper insights into the intricate molecular mechanisms underlying vascular pathology. By scrutinizing the omics approaches of individuals with vascular ailments, researchers can pinpoint potential biomarkers for early detection, devise targeted therapeutic interventions, and enhance patient outcomes. The amalgamation of omics methodologies has yielded novel perspectives on the pathogenesis of vascular pathology and has forged a path toward tailored medical strategies to address these maladies. At its core, leveraging omics in exploring vascular pathology is anticipated to catalyze advancements in our comprehension and management of these intricate health challenges. This Special Issue invites original research and comprehensive reviews on the intersection of vascular diseases and omics.

Guest Editor

Dr. Deepti Diwan

Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA

Deadline for manuscript submissions

closed (30 September 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/213423

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).